Guillain-Barré syndrome after bortezomib therapy in a child with relapsed acute lymphoblastic leukemia. (17th February 2022)

• Record Type: Journal Article
• Authors: Ceolin, Valeria; Cenna, Rosita; Resente, Francesca; Spadea, Manuela; Fagioli, Franca; Bertorello, Nicoletta
• Is Part Of: Pediatric hematology and oncology. Volume 39:Number 2(2022)
• Page Start: 187
• Page End: 192
• Publication Date: 2022-02-17
• Subjects: Bortezomib -- case report -- Guillain-Barré syndrome -- relapsed lymphoblastic leukemia; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Hematologic Diseases -- Child; Hematologic Diseases -- Infant; Neoplasms -- Child; 618.9215
• DOI: 10.1080/08880018.2021.1959691
• Languages: English
• ISSNs: 0888-0018

Abstract

ABSTRACT: A 12-year-old male being treated for a high-risk relapsed T-acute lymphoblastic leukemia presented progressive weakness and numbness of both legs after having received a chemotherapy regimen that included bortezomib. Diagnosis of acute Guillain-Barré syndrome-like inflammatory demyelinating polyneuropathy was made following clinical examination, cerebrospinal fluid analysis, electrodiagnostic studies, magnetic resonance imaging, and serum immunoglobulin antibodies to anti-ganglioside. Intravenous immunoglobulin treatment was started, resulting in complete clinical recovery. Although in rare cases, Guillain-Barré syndrome after bortezomib therapy has been reported; this paper suggests that GBS may occur when bortezomib is administered and high‑dose intravenous immunoglobulin lead to a resolution of the symptoms.